Reaction

Iga Nephropathy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,603 reports · 38 co-occurring drugs

As of the last recalculation, Iga Nephropathy appears in 1,603 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is ATOVAQUONE (PRR 61.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Atovaquone	37	61.1	61.3
Bisacodyl Suppositories	36	36.9	37.0
Biscodyl	36	36.6	36.7
Bisacodyl	36	34.0	34.0
Basiliximab	30	33.7	33.8
Adalimumab-Fkjp	111	33.4	33.4
Adalimumab-Aaty	109	32.0	32.1
Adalimumab-Adaz	109	28.7	28.8
Tacrolimus Extended-Release Capsules	181	21.1	21.1
Tacrolimus Ointment 0.1%	180	21.0	21.0
Tacrolimus	219	20.9	20.9
Mycophenolate Mofetil	184	19.7	19.8
Mycophenolate Mofetil Hydrochloride	184	19.7	19.7
Sirolimus	20	19.5	19.5
Mycophenolic Acid	45	18.8	18.8
Everolimus Tablets	19	14.9	14.9
Infliximab	186	12.4	12.4
Thalidomide	34	12.3	12.3
Panitumumab	14	11.7	11.7
Gefitinib	8	11.6	11.6
Mycophenilic Acid	18	11.4	11.4
Apixaban	49	9.8	9.8
Sotalol Hydrochloride	11	8.6	8.6
Finasteride	37	8.1	8.1
Tofacitinib Citrate	8	8.0	8.0
Dapagliflozin	17	7.1	7.1
Brentuximab Vedotin	5	6.4	6.4
Tenofovir Disoproxil Fumarate Tablets	4	6.0	6.0
Bortezomib	36	5.3	5.3
Trifluridine And Tipiracil	4	4.9	4.9
Nivolumab	35	4.8	4.8
Ustekinumab	34	4.4	4.4
Pomalidomide	31	4.0	4.0
Tenofovir Disoproxil Fumarate	10	3.9	3.9
Ipilimumab	13	3.9	3.9
Ravulizumab	4	3.9	3.9
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	3.6	3.6
Guselkumab	8	2.9	2.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.